Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Dec 26, 2014; 6(12): 1234-1244
Published online Dec 26, 2014. doi: 10.4330/wjc.v6.i12.1234
Published online Dec 26, 2014. doi: 10.4330/wjc.v6.i12.1234
Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges
Bruno Pinamonti, Francesca Brun, Gianfranco Sinagra, Cardiovascular Department, Ospedali Riuniti of Trieste, 34100 Trieste, Italy
Luisa Mestroni, Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Denver AMC, Aurora, CO 80045-2507, United States
Author contributions: Pinamonti B and Brun F contributed equally to the writing of this review article; all the authors contributed to this work.
Correspondence to: Bruno Pinamonti, MD, Cardiovascular Department, Ospedali Riuniti of Trieste, via P. Valdoni n° 7, 34100 Trieste, Italy. bpinamonti@hotmail.com
Telephone: +39-040-3994878
Received: June 5, 2014
Revised: September 3, 2014
Accepted: October 31, 2014
Published online: December 26, 2014
Processing time: 206 Days and 11.7 Hours
Revised: September 3, 2014
Accepted: October 31, 2014
Published online: December 26, 2014
Processing time: 206 Days and 11.7 Hours
Core Tip
Core tip: This manuscript constitutes an update on arrhythmogenic right ventricular cardiomyopathy (ARVC). Recently, molecular genetic studies have provided significant advances in the understanding the pathogenesis of ARVC. However, criteria on treatment with Implantable cardioverter defibrillators are still lacking. We believe that this topic can provide a useful instrument to physicians and guide them in their clinical practice.